started · updated
Medical experts advocate for biosimilars and prescription autonomy
At the “Biosimilares en Cáncer” congress organized by the Fundación Cáncer Vida, clinical specialists, academics, and regulators concluded that biosimilar medicines remain insufficiently integrated into Chile’s health policies. Despite scientific evidence and the potential for significant healthcare savings, experts argue that these treatments lack a relevant presence in national health baskets. Francisco Vidangossy, president of the foundation, noted that the limited use of biosimilars in oncology coverage is difficult to justify given budgetary constraints, and plans to include this issue in the 2027 health budget discussions.
In a separate discussion during the IX National Convention, medical professionals and pharmaceutical industry representatives addressed the reform of the Law on Guarantees and Rational Use of Medicines and Sanitary Products. Medical representatives emphasized the importance of professional autonomy and freedom of prescription, arguing that doctors should remain responsible for prescribing rather than viewing medication solely through an economic lens. The legislative process for this reform was recently interrupted due to the dissolution of the Spanish Parliament, meaning the next government will need to re-initiate the process to update regulations in line with therapeutic innovation and the needs of the National Health System.
Entities
Farmaindustria · Federación de Asociaciones Científico-Médicas Españolas · Fundación Cáncer Vida · ISPOR Chile · Organización Médica Colegial